A randomised study to evaluate the impact of malignant ascites on well-being and the role of breathing exercises in delaying the reaccumulation of recurrent ascites

Submission date 19/08/2002	Recruitment status No longer recruiting	 Prospectively registered Protocol
Registration date 19/08/2002	Overall study status Completed	 Statistical analysis plan Results
Last Edited 31/10/2019	Condition category Cancer	 Individual participant data Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s) Scientific

Contact name Dr - -

Contact details UKCCCR Register Co-ordinator MRC Clinical Trials Unit 222 Euston Road London United Kingdom NW1 2DA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

Study information

Scientific Title

OV4

A randomised study to evaluate the impact of malignant ascites on well-being and the role of breathing exercises in delaying the reaccumulation of recurrent ascites

Study objectives Not provided at time of registration

Ethics approval required Old ethics approval format

Ethics approval(s) Not provided at time of registration

Study design Randomised controlled trial

Primary study design Interventional

Secondary study design Randomised controlled trial

Study setting(s) Not specified

Study type(s) Not Specified

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Ovary cancer

Interventions

Following the first ascitic tap patients are randomised to either:

1. Group A: No initial intervention, on recurrence requiring a second ascitic tap patients are taught breathing exercises and required to wear a form of abdominal binder. Treatment to continue until reaccumulation of ascites.

2. Group B: Patients are taught breathing exercises and required to wear a form of abdominal binder. On recurrence requiring a second ascitic tap patients are given daily diuretic therapy with frusemide and spironolactone until reaccumulation of ascites.

Intervention Type

Other

Phase Not Specified

Primary outcome measure Not provided at time of registration

Secondary outcome measures Not provided at time of registration

Overall study start date 01/01/1992

Completion date

01/05/1997

Eligibility

Key inclusion criteria

- 1. Recurrent abdominal ascites that are a result of relapsed primary resistant cancer of the ovary
- 2. The ascites is asymptomatic and requires drainage
- 3. Patients must not be in sub-acute or complete bowel obstruction
- 4. Performance status <3
- 5. Life expectancy of at least 12 weeks
- 6. No longer receiving chemotherapy
- 7. Adequate haematological profile and biochemistry

Participant type(s)

Patient

Age group Not Specified

Sex Female

Target number of participants Not provided at time of registration

Key exclusion criteria Not provided at time of registration

Date of first enrolment 01/01/1992

Date of final enrolment 01/05/1997

Locations

Countries of recruitment England

United Kingdom

Study participating centre MRC Clinical Trials Unit London United Kingdom NW1 2DA

Sponsor information

Organisation Smith and Nephew Foundation (UK)

Sponsor details 15 Adam Street London United Kingdom WC2N 6LA

Sponsor type Industry

Website http://www.snfoundation.org.uk

ROR https://ror.org/03agge938

Funder(s)

Funder type Research organisation

Funder Name North West Thames Research and Development (UK)

Funder Name

Results and Publications

Publication and dissemination plan Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary Not provided at time of registration